The company that is working on an inhibitor for T315I

[Guest guest]

Structural GenomiX Receives $48.5 Million Award From NIH

Friday July 1, 4:11 pm ET

Award Part of $300 Million NIH Funding Initiative for Protein Structure

Research

SAN DIEGO, July 1 /PRNewswire/ -- Privately-held Structural GenomiX, Inc.

(SGX) today announced receipt of a $48.5 million National Institutes of

Health (NIH) ative Agreement Award from the National Institute of

General Medical Sciences (NIGMS) www.nigms.nih.gov

<http://www.nigms.nih.gov/> . The award is one of ten the NIH announced

today as part of its Protein Structure Initiative (PSI), which aims to

facilitate the discovery of the three-dimensional structures of proteins to

help reveal their role in disease and aid in the design of new medicines.

The NIH award provides five years of renewed funding for a consortium

administered by SGX, the New York Structural GenomiX Research Consortium

(NYSGXRC) (www.nysgxrc.org <http://www.nysgxrc.org/> ). SGX expects to

retain approximately 50 percent of the funding with the remainder to be

distributed to institution collaborators. The NYSGXRC is an

internationally-recognized, industry-academic structural genomics center

that was established by Dr. K. Burley, SGX's chief scientific

officer and senior vice president, during the pilot study phase of the PSI.

Additional participants in the NYSGXRC include scientists at Albert Einstein

College of Medicine, Brookhaven National Laboratory, Columbia University,

and the University of California at San Francisco.

" We are partnering with some of the finest medical research institutions in

the world, " commented Burley.

Under Dr. Burley as principal investigator, SGX will lead the overall

research efforts under this NIH Award and will be responsible for primary

oversight and administration of activities by the institution collaborators,

as well as all gene cloning and expression, purification, and biophysical

characterization of target proteins. SGX will use its proprietary technology

platform to produce high quality and well characterized proteins for

crystallization and structure determination. In addition, SGX will provide

access to its state-of-the-art X-ray beamline at the Advanced Photon Source,

Argonne National Laboratory for structure determination efforts.

" We are pleased that SGX's comprehensive protein structure research efforts

to date laid the groundwork for this NIH award, " stated Dr. Burley.

" Understanding of protein structures plays an integral role in comprehending

complex biological systems and in developing the next generation of drug

targets and medicines. This award gives SGX an unprecedented opportunity to

favorably impact both basic biomedical research and the drug discovery

process. "

About SGX

SGX discovers and develops innovative cancer therapeutics. SGX's lead

product candidate is Troxatyl, a novel cancer therapeutic currently in

Phase 2/3 clinical trials for the treatment of Acute Myelogenous Leukemia

and in Phase 1/2 studies for various solid tumors. SGX has also developed a

preclinical pipeline of novel oncology therapeutics using SGX FAST

technology, a proprietary fragment-based approach to lead generation. The

SGX preclinical oncology pipeline comprises novel inhibitors of wild-type

and GleevecR resistant mutants of BCR-ABL (importantly, T315I) and dual

specificity inhibitors of the MET-RON receptor tyrosine kinases. SGX is also

pursuing a broad program of fragment-based lead generation directed against

a portfolio of validated oncology targets that include HSP-90 and the Aurora

kinases. SGX has secured revenue generating drug discovery and development

partnerships with leading pharmaceutical and biotechnology companies

including Eli Lilly, Serono S.A., and Roche. For more information, please

visit the company's website at www.stromix.com <http://www.stromix.com/> .

About the NIGMS Protein Structure Initiative

For more information about the NIGMS Protein Structure Initiative, visit

http://www.nigms.nih.gov/psi/